Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

[1]  R. Naclerio,et al.  Mediator release after nasal airway challenge with allergen. , 2015, The American review of respiratory disease.

[2]  L. Xue,et al.  A dominant role for chemoattractant receptor‐homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants , 2006, Immunology.

[3]  K. Hirokawa,et al.  Prostaglandin D2 Plays an Essential Role in Chronic Allergic Inflammation of the Skin via CRTH2 Receptor1 , 2006, The Journal of Immunology.

[4]  C. J. Barnes,et al.  Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. , 2006, Immunity.

[5]  G. O'neill,et al.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. Kostenis,et al.  Emerging roles of DP and CRTH2 in allergic inflammation. , 2006, Trends in molecular medicine.

[7]  L. Pardo,et al.  On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2 , 2006, Molecular Pharmacology.

[8]  T. Jacques,et al.  Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Ashley A. Barnes,et al.  9α,11β‐PGF2 and its stereoisomer PGF2α are novel agonists of the chemoattractant receptor, CRTH2 , 2006 .

[10]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[11]  Michael G. Hunter,et al.  Prostaglandin D2 Causes Preferential Induction of Proinflammatory Th2 Cytokine Production through an Action on Chemoattractant Receptor-Like Molecule Expressed on Th2 Cells , 2005, The Journal of Immunology.

[12]  M. Whittaker,et al.  Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. , 2005, Journal of medicinal chemistry.

[13]  T. Lybrand,et al.  Identification of Determinants of Ligand Binding Affinity and Selectivity in the Prostaglandin D2 Receptor CRTH2* , 2005, Journal of Biological Chemistry.

[14]  Evi Kostenis,et al.  A physicogenetic method to assign ligand-binding relationships between 7TM receptors. , 2005, Bioorganic & medicinal chemistry letters.

[15]  M. Pruniaux,et al.  Cutting Edge: Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells Plays a Restricting Role on IL-5 Production and Eosinophil Recruitment , 2005, The Journal of Immunology.

[16]  K. Bacon,et al.  Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview , 2005, Expert opinion on investigational drugs.

[17]  E. Fuse,et al.  Inhibitory Effect of the 4-Aminotetrahydroquinoline Derivatives, Selective Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cell Antagonists, on Eosinophil Migration Induced by Prostaglandin D2 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  D. Robinson,et al.  Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease Severity1 , 2005, The Journal of Immunology.

[19]  M. Pichavant,et al.  Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response , 2005, European journal of immunology.

[20]  N. Varga,et al.  Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[21]  S. Fleury,et al.  Activation of the Prostaglandin D2 Receptor DP2/CRTH2 Increases Allergic Inflammation in Mouse 1 , 2005, The Journal of Immunology.

[22]  T. Lybrand,et al.  Structural Determinants of Arylacetic Acid Nonsteroidal Anti-Inflammatory Drugs Necessary for Binding and Activation of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.

[23]  E. Kostenis,et al.  Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. , 2005, Journal of medicinal chemistry.

[24]  T. Beaty,et al.  Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. , 2004, Human molecular genetics.

[25]  S. Mitsumori.  Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases. , 2004, Current pharmaceutical design.

[26]  L. Palmer,et al.  Role of prostanoid DP receptor variants in susceptibility to asthma. , 2004, The New England journal of medicine.

[27]  R. Breyer,et al.  Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. , 2004, Pharmacology & therapeutics.

[28]  F. Gantner,et al.  CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. , 2004, International immunology.

[29]  S. Dahlén,et al.  Measuring quality of life in patients with sleep apnoea: whose life is it anyway? , 2004, Thorax.

[30]  Masataka Nakamura,et al.  Effects of prostaglandin D2 on helper T cell functions. , 2004, Biochemical and biophysical research communications.

[31]  H. Hammad,et al.  Activation of the D Prostanoid Receptor 1 Regulates Immune and Skin Allergic Responses1 , 2004, The Journal of Immunology.

[32]  G. Sturm,et al.  11-Dehydro-thromboxane B2, a Stable Thromboxane Metabolite, Is a Full Agonist of Chemoattractant Receptor-homologous Molecule Expressed on TH2 Cells (CRTH2) in Human Eosinophils and Basophils* , 2004, Journal of Biological Chemistry.

[33]  F. Gantner,et al.  Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells Activation in Vivo Increases Blood Leukocyte Counts and Its Blockade Abrogates 13,14-Dihydro-15-keto-prostaglandin D2-Induced Eosinophilia in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[34]  H. Hammad,et al.  Prostaglandin D2 Inhibits Airway Dendritic Cell Migration and Function in Steady State Conditions by Selective Activation of the D Prostanoid Receptor 1 1 , 2003, The Journal of Immunology.

[35]  R. Breyer,et al.  Expression and Molecular Pharmacology of the Mouse CRTH2 Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[36]  G. FitzGerald,et al.  Activation of nuclear receptors by prostaglandins. , 2003, Thrombosis research.

[37]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[38]  A. Hartnell,et al.  Δ12-Prostaglandin J2, a Plasma Metabolite of Prostaglandin D2, Causes Eosinophil Mobilization from the Bone Marrow and Primes Eosinophils for Chemotaxis1 , 2003, The Journal of Immunology.

[39]  S. Dahlén,et al.  Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. , 2003, The Journal of allergy and clinical immunology.

[40]  A. Szczeklik,et al.  A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. , 2003, The Journal of allergy and clinical immunology.

[41]  S. Narumiya,et al.  Prostaglandin D2 inhibits the production of interleukin‐12 in murine dendritic cells through multiple signaling pathways , 2003, European journal of immunology.

[42]  F. Gantner,et al.  An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro , 2003, Journal of Pharmacology and Experimental Therapeutics.

[43]  G. O'neill,et al.  Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2 , 2002, British journal of pharmacology.

[44]  J. Rokach,et al.  15-Deoxy-Δ12,1412,14-prostaglandins D2 and J2 Are Potent Activators of Human Eosinophils1 , 2002, The Journal of Immunology.

[45]  Masataka Nakamura,et al.  Cutting Edge: Agonistic Effect of Indomethacin on a Prostaglandin D2 Receptor, CRTH2 , 2002, The Journal of Immunology.

[46]  Yoshihiro Urade,et al.  Pronounced Eosinophilic Lung Inflammation and Th2 Cytokine Release in Human Lipocalin-Type Prostaglandin D Synthase Transgenic Mice1 , 2002, The Journal of Immunology.

[47]  M. Diamond,et al.  Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. , 2001, Blood.

[48]  K. Yasui,et al.  Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. , 2001, The Journal of pharmacology and experimental therapeutics.

[49]  Toshiyuki,et al.  Prostaglandin D_2 as a Mediator of Allergic Asthma. , 2001 .

[50]  E. Gelfand,et al.  IL‐5‐induced airway eosinophilia – the key to asthma? , 2001, Immunological reviews.

[51]  K. Sugamura,et al.  Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2 , 2001, The Journal of experimental medicine.

[52]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[53]  S. Galli,et al.  Mast Cells Can Amplify Airway Reactivity and Features of Chronic Inflammation in an Asthma Model in Mice , 2000, The Journal of experimental medicine.

[54]  J. Wallace,et al.  Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[55]  S. Narumiya,et al.  Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.

[56]  K. Sugamura,et al.  Cutting Edge: Differential Production of Prostaglandin D2 by Human Helper T Cell Subsets , 2000, The Journal of Immunology.

[57]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[58]  K. Sugamura,et al.  CRTH2, an orphan receptor of T‐helper‐2‐cells, is expressed on basophils and eosinophils and responds to mast cell‐derived factor(s) , 1999, FEBS letters.

[59]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[60]  K. Sugamura,et al.  Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family. , 1999, Gene.

[61]  K. Sugamura,et al.  Selective expression of a novel surface molecule by human Th2 cells in vivo. , 1999, Journal of immunology.

[62]  Y. Urade,et al.  Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Y. Urade,et al.  Prostaglandin D2 and sleep regulation. , 1999, Biochimica et biophysica acta.

[64]  スティーヴン・トム,et al.  The novel compounds , 1998 .

[65]  A. Sousa,et al.  Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. , 1997, Thorax.

[66]  S. Dahlén,et al.  Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. , 1996, The Journal of allergy and clinical immunology.

[67]  P. Howarth,et al.  Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. , 1996, Journal of applied physiology.

[68]  N. Hara,et al.  BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. , 1996, Chest.

[69]  A. Kataura,et al.  Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. , 1996, International archives of allergy and immunology.

[70]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[71]  R. Egan,et al.  Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.

[72]  H. Takeda,et al.  The effect of a thromboxane A2 receptor antagonist BAY-u-3405 on experimental allergic reactions. , 1995, Prostaglandins.

[73]  I. Pavord,et al.  Effect of inhaled prostaglandin E2 on allergen-induced asthma. , 1993, The American review of respiratory disease.

[74]  P. Howarth,et al.  The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage. , 1993, The Journal of allergy and clinical immunology.

[75]  S. Johnston,et al.  The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations. , 1992, British journal of clinical pharmacology.

[76]  E. Schulman,et al.  Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. , 1992, Journal of immunology.

[77]  H. Magnussen,et al.  Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction. , 1992, The Journal of allergy and clinical immunology.

[78]  P. Gardiner,et al.  BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro , 1991, British journal of pharmacology.

[79]  R. Rothlein,et al.  The effects of an anti-CD18 antibody (R15.7) in antigen-induced airway hyperresponsiveness (AH) and cell influx in guinea pigs , 1991, Agents and Actions.

[80]  S. Holgate,et al.  Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma. , 1991, Thorax.

[81]  A. Kagey‐Sobotka,et al.  Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. , 1991, Journal of immunology.

[82]  W. Doyle,et al.  Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. , 1990, The Journal of allergy and clinical immunology.

[83]  Y. Urade,et al.  The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. , 1989, Journal of immunology.

[84]  J. Nadel,et al.  Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. , 1989, Journal of applied physiology.

[85]  C. Robinson,et al.  Differential release of histamine and eicosanoids from human skin mast cells activated by IgE‐dependent and non‐immunological stimuli , 1989, British journal of pharmacology.

[86]  S. Holgate,et al.  Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. , 1989, Journal of applied physiology.

[87]  R. A. Coleman,et al.  Prostanoid‐induced contraction of human bronchial smooth muscle is mediated by TP‐receptors , 1989, British journal of pharmacology.

[88]  P. O'Byrne,et al.  Effect of indomethacin on allergen-induced asthmatic responses. , 1989, Journal of applied physiology.

[89]  A. Robertson,et al.  The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist , 1989, British journal of pharmacology.

[90]  S. Dahlén,et al.  Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Holgate,et al.  9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. , 1987, The Journal of clinical investigation.

[92]  J. Murray,et al.  Release of prostaglandin D2 into human airways during acute antigen challenge. , 1986, The New England journal of medicine.

[93]  L. Roberts,et al.  Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[94]  A. Togias,et al.  Inflammatory mediators in late antigen-induced rhinitis. , 1985, The New England journal of medicine.

[95]  C. Dollery,et al.  Effects of intravenous infusions of prostaglandin D2 in man. , 1984, Prostaglandins.

[96]  P. Rao,et al.  The effect of prostaglandin D2 (PGD2) on circulating eosinophils. , 1984, Prostaglandins, leukotrienes, and medicine.

[97]  S. Holgate,et al.  The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. , 1984, The New England journal of medicine.

[98]  K. Frank Austen,et al.  Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human Skin , 1983 .

[99]  J. Oates,et al.  Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. , 1982, Journal of immunology.

[100]  F. Fitzpatrick,et al.  Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. , 1981, The American review of respiratory disease.

[101]  M. Peck,et al.  Role of prostaglandin-mediated vasodilatation in inflammation , 1977, Nature.

[102]  R. J. Flower,et al.  INFLAMMATORY EFFECTS OF PROSTAGLANDIN D2 IN RAT AND HUMAN SKIN , 1976, British journal of pharmacology.

[103]  Chris Allan,et al.  Delta12-prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes. , 2005, Prostaglandins & other lipid mediators.

[104]  G. O'neill,et al.  Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa , 2004 .

[105]  T. Lybrand,et al.  Structural determinants of arylacetic acid NSAIDs necessary for binding and activation of the PGD 2 receptor CRTH2 , 2004 .

[106]  M. J. Leckie.  Anti-Interleukin-5 Monoclonal Antibodies , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[107]  A. Hartnell,et al.  Causes Eosinophil Mobilization from the Bone Marrow and Primes Eosinophils for Chemotaxis , 2003 .

[108]  R. Pauwels,et al.  Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[109]  Lu Jin.  Prostaglandin D_2 and sleep regulation , 2002 .

[110]  A. Konno,et al.  The effect of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. , 1998, Acta oto-laryngologica. Supplementum.

[111]  K. P. Hui,et al.  Effects of a thromboxane receptor antagonist on prostaglandin D2 and histamine induced bronchoconstriction in man. , 1994, British journal of clinical pharmacology.

[112]  Coleman Ra.  GR32191 and the role of thromboxane A2 in asthma--preclinical and clinical findings. , 1991 .

[113]  D. Woodward,et al.  Studies on the ocular pharmacology of prostaglandin D2. , 1990, Investigative ophthalmology & visual science.

[114]  B. Whittle,et al.  Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets. , 1985, Advances in experimental medicine and biology.

[115]  E. Corey,et al.  Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. , 1983, The Journal of investigative dermatology.

[116]  R. Naclerio,et al.  The role of prostaglandin D2 in IgE-mediated reactions in man. , 1982, Transactions of the Association of American Physicians.